- Home
- BX vs TOVX Comparison
BX vs TOVX Comparison
Compare BX & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BX | TOVX |
|---|---|---|
| Founded | 1985 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.8B | 7.3M |
| IPO Year | 2007 | 2006 |
Fundamental Metrics
Financial Performance| Metric | BX | TOVX |
|---|---|---|
| Price | $155.36 | $0.19 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 15 | 1 |
| Target Price | ★ $180.20 | N/A |
| AVG Volume (30 Days) | ★ 3.9M | 3.1M |
| Earning Date | 01-29-2026 | 11-12-2025 |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | ★ 19.48 | N/A |
| EPS | ★ 3.48 | N/A |
| Revenue | ★ $12,791,218,000.00 | N/A |
| Revenue This Year | $3.97 | N/A |
| Revenue Next Year | $24.91 | N/A |
| P/E Ratio | $44.59 | ★ N/A |
| Revenue Growth | ★ 14.84 | N/A |
| 52 Week Low | $115.66 | $0.17 |
| 52 Week High | $190.09 | $2.08 |
Technical Indicators
Market Signals| Indicator | BX | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 59.33 | 41.74 |
| Support Level | $151.04 | $0.17 |
| Resistance Level | $156.75 | $0.22 |
| Average True Range (ATR) | 3.79 | 0.02 |
| MACD | 0.49 | 0.00 |
| Stochastic Oscillator | 70.21 | 34.39 |
Price Performance
Historical ComparisonAbout BX Blackstone Inc.
Blackstone is the world's largest alternative-asset manager with $1.167 trillion in total asset under management, including $860.1 billion in fee-earning assets under management, at the end of March 2025. The company has four core business segments: private equity (26% of fee-earning AUM and 30% of base management fees), real estate (34% and 40%), credit and insurance (32% and 23%), and multi-asset investing (8% and 7%). While the firm primarily serves institutional investors (87% of AUM), it also caters to clients in the high-net-worth channel (13%). Blackstone operates through 25 offices in the Americas (8), Europe and the Middle East (9), and the Asia-Pacific region (8).
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.